Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Washed leukoreduced irradiated blood cell transfusions represent a specialized biological product used primarily in high-risk clinical settings, such as pediatric cardiac surgery. The preparation involves three distinct processing steps: **washing**, which replaces donor plasma with saline to remove inflammatory mediators (e.g., IL-6, IL-10), extracellular potassium, and plasma proteins that cause allergic reactions; **leukoreduction**, which removes donor white blood cells to prevent febrile non-hemolytic transfusion reactions and HLA alloimmunization; and **irradiation**, which uses ionizing radiation to inactivate donor T-lymphocytes, thereby preventing Transfusion-Associated Graft-Versus-Host Disease (TA-GVHD). This combination is specifically investigated for its ability to mitigate the systemic inflammatory response syndrome (SIRS) associated with cardiopulmonary bypass in children undergoing repair of congenital heart defects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on washed leukoreduced irradiated blood cells.